Epigallocatechin-3-gallate inhibits migration and invasion of human renal carcinoma cells by downregulating matrix metalloproteinase-2 and matrix metalloproteinase-9

Experimental and Therapeutic Medicine

Volumn 11, Issue 4, 2016, Pages 1243-1248

  Chen, Shao Jun ^a   Yao, Xu Dong ^a   Peng, Bo ^a   Xu, Yun Fei ^a   Wang, Guang Chun ^a   Huang, Jianhua ^a   Liu, Min ^a   Zheng, Jun Hua ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Epigallocatechin 3 gallate; Invasion; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Migration; Renal cell carcinoma

Indexed keywords

EPIGALLOCATECHIN GALLATE; GELATINASE A; GELATINASE B;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CENTRIFUGATION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCIDENCE; KIDNEY CARCINOMA; MTT ASSAY; RADIOIMMUNOPRECIPITATION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY;

EID: 84958781279     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2016.3050     Document Type: Article

References (33)

1. Xue YJ, Xiao RH, Long DZ, Zou XF, Wang XN, Zhang GX, Yuan YH, Wu GQ, Yang J, Wu YT, et al: Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma. J Transl Med 10: 200, 2012.
2. Mancuso A and Sternberg CN: New treatments for metastatic kidney cancer. Can J Urol 12 (Suppl 1): S66-S70; discussion 105, 2005.
3. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA and Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20: 4559-4566, 2002.
4. Cohen HT and McGovern FJ: Renal-cell carcinoma. N Engl J Med 353: 2477-2490, 2005.
5. Chambers AF, MacDonald IC, Schmidt EE, Morris VL and Groom AC: Clinical targets for anti-metastasis therapy. Adv Cancer Res 79: 91-121, 2000.
6. Bracken CP, Gregory PA, Khew-Goodall Y and Goodall GJ: The role of microRNAs in metastasis and epithelial-mesenchymal transition. Cell Mol Life Sci 66: 1682-1699, 2009.
7. Cakarovski K, Leung JY, Restall C, Carin-Carlson A, Yang E, Perlmutter P, Anderson R, Medcalf R and Dear AE: Novel inhibitors of urokinase-type plasminogen activator and matrix metalloproteinase expression in metastatic cancer cell lines. Int J Cancer 110: 610-616, 2004.
8. Toda D, Ota T, Tsukuda K, Watanabe K, Fujiyama T, Murakami M, Naito M and Shimizu N: Gefitinib decreases the synthesis of matrix metalloproteinase and the adhesion to extracellular matrix proteins of colon cancer cells. Anticancer Res 26: 129-134, 2006.
9. Nelson AR, Fingleton B, Rothenberg ML and Matrisian LM: Matrix metalloproteinases: Biologic activity and clinical implications. J Clin Oncol 18: 1135-1149, 2000.
10. Stoner GD and Mukhtar H: Polyphenols as cancer chemopreventive agents. J Cell Biochem Suppl 22: 169-180, 1995.
11. Katiyar S and Mukhtar H: Tea in chemoprevention of cancer. Int J Oncol 8: 221-238, 1996.
12. Chen D, Wan SB, Yang H, Yuan J, Chan TH and Dou QP: EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem 53: 155-177, 2011.
13. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24: 747-757, 2010.
14. Lim YC, Park HY, Hwang HS, Kang SU, Pyun JH, Lee MH, Choi EC and Kim CH: (-)-Epigallocatechin-3-gallate (EGCG) inhibits HGF-induced invasion and metastasisin hypopharyngeal carcinoma cells. Cancer Lett 271: 140-152, 2008.
15. Siddiqui IA, Malik A, Adhami VM, Asim M, Hafeez BB, Sarfaraz S and Mukhtar H: Green tea polyphenol EGCG sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated apoptosis and synergistically inhibits biomarkers associated with angiogenesis and metastasis. Oncogene 27: 2055-2063, 2008.
16. Shankar S, Ganapathy S, Hingorani SR and Srivastava RK: EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 13: 440-452, 2008.
17. Volpe A and Patard JJ: Prognostic factors in renal cell carcinoma. World J Urol 28: 319-327, 2010.
18. Qiao HP, Gao WS, Huo JX and Yang ZS: Long non-coding RNA GAS5 functions as a tumor suppressor in renal cell carcinoma. Asian Pac J Cancer Prev 14: 1077-1082, 2013.
19. Zhang L, Xul B, Chen S, Lu K, Liu C, Wang Y, Zhao Y, Zhang X, Liu D and Chen M: The complex roles of microRNAs in the metastasis of renal cell carcinoma. J Nanosci Nanotechnol 13: 3195-3203, 2013.
20. Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30: 843-852, 2003.
21. Waas ET, Wobbes T, Lomme RM, DeGroot J, Ruers T and Hendriks T: Matrix metalloproteinase 2 and 9 activity in patients with colorectal cancer liver metastasis. Br J Surg 90: 1556-1564, 2003.
22. Zhang L, Shi J, Feng J, Klocker H, Lee C and Zhang J: Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. Prostate Cancer Prostatic Dis 7: 327-332, 2004.
23. Ma J, Fang B, Zeng F, Pang H, Zhang J, Shi Y, Wu X, Cheng L, Ma C, Xia J and Wang Z: Curcumin inhibits cell growth and invasion through up-regulation of miR-7 in pancreatic cancer cells. Toxicol Lett 231: 82-91, 2014.
24. Lee HS, Ha AW and Kim WK: Effect of resveratrol on the metastasis of 4T1 mouse reast cancer cells in vitro and in vivo. Nutr Res Pract 6: 294-300, 2012.
25. Kim HJ, Kim SK, Kim BS, Lee SH, Park YS, Park BK, Kim SJ, Kim J, Choi C and Kim JS: Apoptotic effect of quercetin on HT-29 colon cancer cells via the AMPK signaling pathway. J Agric Food Chem 58: 8643-8650, 2010.
26. Luo HQ, Xu M, Zhong WT, Cui ZY, Liu FM, Zhou KY and Li XY: EGCG decreases the expression of HIF-1α and VEGF and cell growth in MCF-7 breast cancer cells. J BUON 19: 435-439, 2014.
27. Sakamoto Y, Terashita N, Muraguchi T, Fukusato T and Kubota S: Effects of epigallocatechin-3-gallate (EGCG) on A549 lung cancer tumor growth and angiogenesis. Biosci Biotechnol Biochem 77: 1799-1803, 2013.
28. Lee JH, Jeong YJ, Lee SW, Kim D, Oh SJ, Lim HS, Oh HK, Kim SH, Kim WJ and Jung JY: EGCG induces apoptosis in human laryngeal epidermoid carcinoma Hep2 cells via mitochondria with the release of apoptosis-inducing factor and endonuclease G. Cancer Lett 290: 68-75, 2010.
29. Chambers AF and Matrisian LM: Changing views on the role of matrix metalloprotenases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997.
30. Kleiner DE and Stetler-Stevenson WG: Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43 (Suppl): S42-S51, 1999.
31. Deng YT and Lin JK: EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. J Agric Food Chem 59: 13318-13327, 2011.
32. Sen T, Dutta A and Chatterjee A: Epigallocatechin-3-gallate (EGCG) downregulates gelatinase-B (MMP-9) by involvement of FAK/ERK/NFkappaB and AP-1 in the human breast cancer cell line MDA-MB-231. Anticancer Drugs 21: 632-644, 2010.
33. Kim HS, Kim MH, Jeong M, Hwang YS, Lim SH, Shin BA, Ahn BW and Jung YD: EGCG blocks tumor promoter-induced MMP-9 expression via suppression of MAPK and AP-1 activation in human gastric AGS cells. Anticancer Res 24: 747-753, 2004.